Seeing Is Believing
Currently out of the existing stock ratings of Bill Maughan, 11 are a BUY (64.71%), 6 are a HOLD (35.29%).
Analyst Bill Maughan, currently employed at CANACCORD, carries an average stock price target met ratio of 44.44% that have a potential upside of 59.06% achieved within 180 days.
Bill Maughan’s has documented 33 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on FATE, Fate Therapeutics at 09-May-2024.
Analyst best performing recommendations are on DCTH (DELCATH SYSTEMS).
The best stock recommendation documented was for IMCR (IMMUNOCORE HOLDINGS LTD) at 2/29/2024. The price target of $63 was fulfilled within 8 days with a profit of $4.22 (6.28%) receiving and performance score of 7.85.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$31
$19.03 (158.98%)
$29
2 months 11 days ago
(07-Aug-2025)
3/14 (21.43%)
$20.81 (204.22%)
715
Buy
$22
$10.03 (83.79%)
$20
7 months 12 days ago
(06-Mar-2025)
1/4 (25%)
$8.78 (66.41%)
36
Buy
$21
$9.03 (75.44%)
$18
2 years 1 months 11 days ago
(07-Sep-2023)
2/5 (40%)
$16.4 (356.52%)
716
Buy
$13
$1.03 (8.60%)
$25
2 years 2 months 2 days ago
(16-Aug-2023)
2/4 (50%)
$7.59 (140.30%)
382
Buy
$14
$2.03 (16.96%)
$17
2 years 10 months 27 days ago
(21-Nov-2022)
2/2 (100%)
$11.06 (376.19%)
907
What Year was the first public recommendation made by Bill Maughan?